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ABSTRACT
The membrane-anchored glycoprotein RECK negatively regulates multiple 
metalloproteinases and is frequently downregulated in tumors. Forced RECK 
expression in cancer cells results in suppression of tumor angiogenesis, invasion, 
and metastasis in xenograft models. A previous methylome study on breast cancer 
tissues detected inverse correlation between RECK CpG methylation (in an intron-1 
region) and relapse-free survival. In this study, we focused on another region of 
the RECK CpG island (a promoter/exon-1 region) and found an inverse correlation 
between its methylation and RECK-inducibility by an HDAC inhibitor, MS275, among 
a panel of breast cancer cell lines (n=15). In clinical samples (n=62), RECK intron-1 
methylation was prevalent among luminal breast cancers as reported previously (26 
of 38 cases; 68%) and particularly enriched in tumors of the ER+PR- subclass (10 of 
10 cases) and of higher histological grades (Grade 2 and 3; 28 of 43 cases; P=0.006). 
In about a half of these cases, promoter/exon-1 methylation was absent, and hence, 
RECK may be inducible by certain drugs such as MS275. Our results indicate the value 
of combined use of two RECK methylation markers for predicting prognosis and drug-
sensitivity of breast cancers.
INTRODUCTION
Breast cancer, a major health concern worldwide [1], 
exhibits disparate clinical behaviors and patient outcomes 
[2]. Ductal carcinoma in situ (DCIS) is a non-invasive 
breast lesion that accounts for 10-25% of all breast 
neoplasms; DCIS is not life-threatening but a risk factor 
for, and potential precursor of, invasive cancers. The most 
common histological type of breast cancers, accounting 
for ~80% of the cases, is invasive ductal carcinoma (IDC). 
IDC has been subgrouped based on immunohistochemical 
detection of several markers such as estrogen receptor 
(ER), progesterone receptor (PR), and epidermal growth 
factor receptor 2 (HER2). A large fraction (70–75%) of 
IDCs are positive for ER and classified as luminal cancers. 
A small fraction of luminal cancers are positive for HER2 
and called luminal HER2. PR expression usually follows 
the ER expression but can be low in some cases where 
prognoses tend to be poorer. Two major subtypes, besides 
luminal cancers, are HER2-enriched and triple-negative 
(ER-/PR-/HER2-) [2]. HER2-enriched cancers show 
amplification and high expression of the ERBB2 gene 
and several other genes of the ERBB2 amplicon. Breast 
cancer classification based on gene expression profiles 
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has also been proposed [3]. Such molecular classifications 
of cancers are of great clinical importance, since they 
may provide molecular bases for predicting the tumors’ 
prognoses and/or responses to therapy [2].
Altered patterns of DNA methylation are found 
in cancer cells, and their values as potential biomarkers 
for diagnoses and prognoses have been explored [4]. 
For example, attempts to correlate genome-wide DNA 
methylation patterns in breast cancers and their prognoses 
have been made [5–7]. Since epigenetic silencing of tumor 
suppressor genes is involved in carcinogenesis, inhibitors of 
certain epigenetic regulators, such as DNA methyl transferases 
(DNMTs) and histone deacetylases (HDACs), have been 
tested in cancer therapy with promising results [8–10]. In 
fact, two DNMT inhibitors, 5-azacytidine and 5-aza-2′-
deoxycytidine (decitabine), have already been approved by 
FDA for treatment of myelodysplastic syndrome [11, 12].
RECK, initially isolated as a transformation 
suppressor gene by cDNA-expression cloning, encodes a 
GPI-anchored glycoprotein with activities to downregulate 
or inhibit multiple metalloproteinases [13, 14]. Reduced 
RECK expression is found in various types of tumors, 
and the levels of residual RECK expression in tumors 
tend to correlate with better prognoses [15, 16]. In gene-
focused studies, extensive methylation of RECK CpG 
island has been found in cancers of the colon, stomach, 
liver, and lung, and its correlation with poorer prognoses 
detected [17–22]. Importantly, in a non-biased, genome-
wide methylation study, Hill and colleagues detected 
RECK as one of several loci whose methylation inversely 
correlated with relapse-free survival among breast cancer 
patients [5]. They employed an assay called Combined 
Bisulfite Restriction Analysis (COBRA) [23] for rapid 
detection of CpG methylation; in the case of RECK, they 
used a set of PCR primers amplifying an intron-1 region 
of its CpG island (see Figure 1A, bottom line). We refer 
to the methylation of this region “RIM” (RECK Intron-1 
Methylation) in this paper to distinguish it from a newly 
examined region (see below).
Involvement of DNMT3B in oncogene-induced 
RECK gene silencing [24] and induction of RECK 
expression by DNMT inhibitors [17, 20, 21, 24–26] have 
been reported. RECK activation by an HDAC inhibitor, 
trichostatin A (TSA), has also been observed in several 
systems [27–32], suggesting the involvement of histone 
modifications. Besides these epigenetic regulations, 
multiple other mechanisms of RECK downregulation, 
such as signaling triggered by growth factors, cell density, 
oncoproteins, hypoxia, and post-transcriptional inhibition 
by microRNAs, have also been reported [29, 30, 32–34].
Figure 1: RECK methylation and expression in breast cancer cell lines. A. Positions of exon-1 (green line), first methionine 
(red diamond), CpG island (orange line), and the COBRA target region described by Hill et al. (RIM, blue line) [5] in which three BstU1 
sites (vertical lines) exist. Nucleotide sequence of this region is shown in Supplementary Figure S1. B. RECK CpG methylation (RIM) in 
14 cell lines detected by COBRA. Appearance of smaller bands after BstU1-digestion (even number lanes) indicates methylation of the 
BstU1 site (CGCG). C. RIM determined by clone-sequencing. The PCR products used for COBRA were cloned into bacterial plasmids, 
and 12 independent plasmid clones (represented by each line) sequenced. Methylation status of 22 CpG di-nucleotides (column 1-22) 
within the amplified area is shown using open (non-methylated) or filled circles (methylated). Solid triangles on the top indicate BstU1 sites 
(Supplementary Figure S2, red triangles). D. The levels of RECK protein detected by immunoblot assay (IB; upper autoradiographs) and 
RECK mRNA detected by qRT-PCR (lower bar graph). GAPDH was used as an internal control in IB; RNA from normal human fibroblasts 
(MRC5) was used as a positive control in qRT-PCR. Top line indicates the RIM status estimated from B and C.
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In the present study, we designed a new set of 
primers amplifying a region of RECK CpG island 
containing the proximal promoter and exon-1 (see Figure 
3A, bottom line); we refer to the methylation of this 
region “RPM” (RECK Promoter/exon-1 Methylation). Our 
data indicate the utility of RIM and RPM as distinctive 
molecular markers useful for sub-grouping luminal 
breast cancers and their potential values in predicting the 
prognoses and drug-sensitivity of breast cancers.
RESULTS
RECK CpG methylation in breast cancer cell lines
Focusing on the intro-1 region of the RECK CpG 
island, Hill and colleagues found a significant inverse 
correlation between its methylation (RIM) in tumor 
tissues and relapse-free survival of the patients [5]. Their 
data also suggested the prevalence of RIM in the tumors 
positive for ER (P=0.013) and those at relatively early 
stages (P=0.022) (Supplementary Table S2).
To confirm and extend these important findings, we 
applied the same COBRA protocols to analyze RIM in 16 
cell lines, one derived from normal mammary epithelium 
(MCF-10A) and 15 from breast cancers of various 
subtypes (Figure 1B; Supplementary Figure S1). RIM 
was detected in 8 of 15 cancer-derived cell lines (53%) 
but not in MCF-10A (Table 1). The COBRA results were 
confirmed by sequencing individual PCR products cloned 
into a bacterial plasmid (Figure 1C and data not shown). 
The pattern of RIM distribution among breast cancer 
subtypes is largely recapitulated in this small set of cell 
lines: significant enrichment of RIM in luminal cancers 
(5 of 5) and its paucity in triple negative cancers were 
detected (1 of 7; Table 1A, 1B, “RIM” column). RECK 
expression (both mRNA and protein) is low in cell lines 
positive for RIM (Figure 1D), suggesting the involvement 
of RIM in RECK silencing. These data also suggest the 
value of these cell lines in studying how RIM affects 
RECK expression and the properties of breast cancer cells.
Effects of DNMT inhibitor and HDAC inhibitor 
on RECK expression
To test the effects of CpG methylation on RECK 
expression, we treated some of these cell lines with a 
DNMT inhibitor, 5-aza-2′-deoxycytidine (5-azadC), and 
determined the levels of RECK mRNA and protein. We 
also examined the effects of an HDAC inhibitor, MS275, 
which we found to induce RECK expression in some other 
cell lines, such as those derived from human fibrosarcoma 
(Yoshida et al., unpublished). First, we confirmed the 
effects of 5-azadC to reduce RIM in three luminal cell 
lines (MCF7, T-47D, ZR-75-1) by COBRA; the increased 
intensity of full-length band and decreased intensity of 
smaller bands in BstU1-digested samples after 5-azadC-
treatment (Figure 2A–2C, compare lane 4 to lane 2) 
indicate successful DNA demethylation. MS275, on the 
other hand, exhibited little effects on RIM (Figure 2A–
2C, compare lane 6 to lane 2). In these cell lines, 5-azadC 
alone (namely, demethylation alone) showed little effect 
on RECK expression (Figure 2D–2F, bar/lane 2). In two 
RIM-positive cell lines, T-47D and ZR-75-1, combination 
of two inhibitors (5-azadC and MS275) was effective in 
activating RECK expression (Figure 2E, 2F, bar/lane 4) 
while MS275 alone was not so effective (Figure 2E, 2F, 
bar/lane 3). In a RIM-negative cell line, MDA-MB-231, 
MS275 alone was sufficient to induce robust RECK 
expression (Figure 2G), supporting the idea that RIM 
may be useful in predicting whether or not demethylation 
is prerequisite for MS275-induced RECK expression. 
The response of RECK in the RIM-positive MCF7 
cells, however, did not support this idea; MS275 could 
upregulate RECK mRNA to some extent but 5-azadC 
failed to enhance this effect in MCF7 (Figure 2D, bar/
lane 3, 4). Survey of additional cell lines yielded another 
example of RIM-positive cell line, HCC1954, in which 
RECK could be upregulated by MS275 alone (Figure 2H) 
although the methylation seems to be incomplete in this 
case (Figure 1B, lane 18).
RECK promoter/exon-1 methylation (RPM) 
in breast cancer cell lines
Why MS275 could upregulate RECK expression 
in some RIM-positive cells but not others? To test the 
possibility that we were focusing on an area inappropriate 
for predicting cell’s response to MS275, we designed a new 
set of COBRA primers to monitor methylation of more 
upstream region of RECK CpG island (RPM; Figure 3A, 
bottom line). Among the 15 breast cancer cell lines, three 
(T-47D, ZR-75-1, MDA-MB-453) were positive for 
RPM (Figure 3B; Table 1); the results were confirmed by 
clone-sequencing (Figure 3C). As expected, RPM could 
be reduced by 5-azadC in these cell lines (Figure 3D–3F, 
compare lane 4 to lane 2) but not by MS275 (Figure 3D–3F, 
compare lane 6 to lane 2).
Importantly, the extent of RPM at the sequence level 
(Figure 3C) differs dramatically between MCF7 (1.1%) and 
two other luminal cell lines, T-47D (55 %) and ZR-75-1 
(90%). The other MS275-responsive cell line HCC1954 
(Figure 2H) was also RPM-negative (Figure 3B, lane 20). 
Thus, RPM better predicts the cells’ response to MS275 
than RIM. In this small set of cell lines, however, no 
significant association of RPM to certain tumor subtype 
could be detected (Table 1B, “RPM” column).
RPM and RIM in breast cancer tissues
To better understand the biological and clinical 
significance of above findings in cell lines, we 
compared RPM, RIM, and the level of RECK mRNA 
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in tissue samples from 62 breast cancer patients (results 
summarized in Figure 4 and Table 2; representative data 
shown in Supplementary Figures S4 and S5). Several 
findings of potential importance were noted. First, 
comparison between matched pairs of normal and tumor 
tissues (n=13) indicated significant downregulation of 
RECK mRNA (P=0.001; Figure 4A) and prevalence of 
RECK CpG methylation, both RPM and RIM, in tumor 
tissues (Figure 4B, bar 2, 4). Second, when 62 tumor 
samples were divided into two groups based on RECK 
methylation status (RPM or RIM), the average level of 
RECK mRNA was lower in the RIM+ group than the 
RIM- group, although the difference was not statistically 
significant (P=0.055; Figure 4C, bar 3, 4). RECK mRNA 
was relatively abundant in luminal tumors (Supplementary 
Figure S6A), and within this subtype, significant 
correlation between RIM and lower RECK expression was 
detected (P=0.041; Figure 4C, bar 5). Third, as we found 
in cell lines (Table 1B, 1A), frequency of RIM among 
tumor samples (33 of 62 cases; 53%) was higher than that 
of RPM (16 of 62; 26%), and majority of RPM+ tumors 
(15 of 16; 94%) were also RIM+ (Figure 4D). Fourth, both 
B
Sub-total RPM RIM
n Fraction (%) n P n P
Normal 1 6 0 NS (0.63) 0 NS (0.32)
Luminal 5 31 2 NS (0.22) 5 0.025
HER2 3 19 1 NS (0.52) 2 NS (0.56)
TN 7 44 0 NS (0.20) 1 NS (0.059)
Total 16 100 3 8
P was assessed by Pearson’s chi-squared test. NS, not significant
Table 1: Summary of data on breast cancer-derived cell lines
A
Cell line Subtype Medium1) ER PR HER2 RPM (%) RIM (%)
MCF10A Normal M - - - - -
MCF7 Luminal D + + - 1.1 82
T-47D Luminal R + + - 55 48
ZR-75-1 Luminal R + +/- - 90 86
KPL-1 Luminal R + - - - +2)
KPL-3C Luminal R + - - - +2)
MDA-MB-453 HER2 D - - + 90 82
SK-BR-3 HER2 R - - + - -
HCC1954 HER2 R - - + 0.9 74
MDA-MB-468 TN R - - - - -
HCC1937 TN D (HG) - - - - -
MDA-MB-231 TN D - - - 0.3 -
BT549 TN R - - - - -
HCC38 TN R - - - - -
Hs578-T TN DI - - - - -
SUM-159PT TN F - - - - 17
1) M, MEGM; D, DME + 10% FBS, R, RPMI + 10% FBS; HG, high glucose; DI, DME + 10% FBS, 10 μg/ml bovine 
insulin; F, Ham’s F12 + 5%FBS, 5 μg/ml insulin,1 μg/ml hydrocortisone,10 mM HEPES
2) Analyzed only by COBRA (See Supplementary Figure S1).
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Figure 2: Effects of 5-azadC and MS275 on RIM and RECK expression. A–C. RIM detected by COBRA in three breast 
cancer cell lines [MCF7 (A), T-47D (B), or ZR-75-1 (C)] after incubation under indicated conditions. D–F. Effects of 5-azadC and/or 
MS275 on the level of RECK mRNA detected by qRT-PCR (upper bar graph) and RECK protein detected by immunoblot assay (lower 
autoradiographs) in MCF7 (D), T-47D (E), or ZR-75-1 (F). G, H. Effects of MS275 on the level of RECK mRNA and protein in two breast 
cancer cell lines: MDA-MB-231 (G) and HCC1954 (H).
Figure 3: RECK gene methylation detected by new COBRA primers. A. Position of RPM (orange line) with respect to the 
RECK CpG island (brown line) and the original COBRA target (RIM; blue line). Four BstU1 sites (vertical lines), two of which are 
tandem, exist within the RPM region. Nucleotide sequence of this region is shown in Supplementary Figure S3. B. RPM status in 14 cell 
lines detected by COBRA. C. RPM status in four cell lines determined by clone-sequencing. Methylation status of 37 CpG di-nucleotides 
(column 1-37) within the amplified area is shown. Solid triangles on the top indicate BstU1 sites (Supplementary Figure S3, red triangles). 
D–F. Effects of 5-azadC and/or MS275 on RPM status detected by COBRA in T-47D (D), ZR-75-1 (E), and MDA-MB-453 (F). Note the 
increased full-length band (representing non-methylated allele) and decreased smaller bands (methylated allele) in BstU1-digested samples 
(even-numbered lanes) after treatment with 5-azadC (compare lanes 4, 8 to lane 2) but not with MS275 (compare lane 6 to lane 2). Non, 
band representing to non-methylated DNA; Me, bands representing methylated DNA; MI, ratio of methylated CpG to all CpG.
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RPM and RIM were prevalent in luminal/ER+ tumors 
(Figure 4E; Table 2). Fifth, RECK CpG methylation (both 
RPM and RIM) was negative, althogh RECK mRNA was 
minimal, in DCIS (n=6; Table 2 ; Supplementary Figure 
S6A). Sixth, all the ER+PR- tumors were positive for RIM 
(10 of 10; Table 2). Seventh, RECK CpG methylation, 
especially RIM, correlates with higher tumor stages and 
histological grades (Table 2), supporting the idea that the 
RECK silencing (associated with RIM) contributes to the 
malignant behaviors of breast cancer cells.
Effects of MS275 on RECK promoter
How does MS275 upregulate RECK in RPM-
negative breast cancer cells? We confirmed that MS275 
increased the level of acetylated histones, as monitored 
using acetylated H4 (Ac-H4), in three cell lines: MCF7 
(RPM-RIM+), T-47D (RPM+RIM+), and MDA-MB-231 
(RPM-RIM-) (Supplementary Figure S7B–S7D, lanes 1, 
2). As detected by chromatin immunoprecipitation (ChIP) 
assay, MS275 increased the amount of Ac-H4 bound to 
three regions (termed P1, P2, and E1; Supplementary 
Figure S7A) upstream of, or containing, RECK exon-
1 (Supplementary Figure S7B–S7D, lanes 5, 6). The 
increase (especially in E1) seems to be modest in T-47D 
cells (RPM+) (Supplementary Figure S7C, lanes 5, 
6). Second, association of HDAC1, a known target 
of MS275, to the RECK promoter was confirmed by 
ChIP assay (Supplementary Figure S7E, S7F). Relative 
intensity of 3 ChIP bands differed between cell lines: P1 
was most intense in T-47D while E1 was most intense in 
MDA-MB-231, although biological significance of this 
difference is unclear. Third, knockdown of HDAC1 using 
two siRNAs (#1, #2), resulted in RECK-upregulation in 
MDA-MB-231 cells (Supplementary Figure S7G, lanes 
4, 5). These data are consistent with the idea that MS275 
upregulates RECK (in RPM-negative breast cancer cell 
lines) by inhibiting HDAC1, thereby increasing the 
acetylation of its targets.
Biological significance of RECK-inducibility
RPM was inversely correlated with the cells’ ability 
to express RECK in response to MS275 (Figure 2; Table 
1). Is there any biological significance or clinical relevance 
in this finding? To address this issue, we first assessed the 
effects of MS275, 5-azadC, or both on the growth/surival 
of T-47D cells (RPM+RIM+; Figure 5A, 5B). Although 
the growth was suppressed to some extent by treatment 
with MS275 alone or 5-azadC alone (Figure 5A, blue and 
Figure 4: Statuses of RECK mRNA, RPM, and RIM in human breast tissues. A. RECK mRNA in normal and tumor tissues 
from the same patients (n=14). B. Proportions of RPM+ and RIM+ cases among the normal (blue) and tumor (red) tissues. C. Relationship 
between the status of RPM or RIM and the level of RECK mRNA. D. Relationship among breast cancer subgroups exhibiting different 
RPM/RIM statuses. Their relationship with ER+PR- tumors is also shown. E. Distribution of molecular subtypes [DCIS, luminal (Lum), 
HER2-enriched (HER2), and triple negative (TN)] among total (bars 1-4), RPM-positive (bars 5-8), or RIM-positive (bars 9-12) breast 
cancer cases. F. Distribution of tumors with different RPM/RIM statuses in each molecular subtype. G. Three classes of cells with different 
RPM/RIM statuses. [1] When RPM and RIM are negative, RECK is likely to be expressed, albeit at lower levels in tumors. [2] When 
methylation is confined to RIM, RECK is silent but inducible by MS275. [3] When both RPM and RIM are positive, RECK is silent and 
insensitive to MS275 unless the CpG island has been demethylated. Some cell lines of each class are listed on the right-hand side.
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red lines; Figure 5B-2, 3), almost complete cell killing was 
observed only after combined treatment (Figure 5A, green 
line; Figure 5B-4).
Next, we treated four cell lines that exhibit different 
RECK methylation patterns [T-47D (RPM+RIM+), MCF7 
(RPM-RIM+), BT549 and SKBR3 (RPM-RIM-)] with a 
RECK-activating anticancer drug, methotrexate (MTX) 
[35]. T-47D (RPM+) showed lowest sensitivity to this drug 
(Figure 5C; red line). Acute expression of RECK using 
adenoviral vector made T-47D cells susceptible to MTX 
(Figure 5D, black line), suggesting possible contribution 
of RECK in MTX-induced growth inhibition.
Finally, we subjected two cell lines, T-47D and 
MDA-MB-231, to Matrigel invasion assay in the 
absence or presence of MS275 (Figure 5E, 5F) and found 
significant suppression of invasion by MS275 in MDA-
MB-231 cells (RPM-; Figure 5F) but not in T-47D cells 
(RPM+; Figure 5E). Taken together, these results support 
Table 2: Clinicopathological features and methylation at two regions of RECK CpG island (RPM and RIM) in breast 
cancer tissues
n RPM RIM
Number Ratio P Number Ratio P
+ - RPM+/n 
(%)
+ - RIM+/n 
(%)
Total 62 16 46 26 33 29 53
Age <55 20 4 16 20 NS (0.47) 10 10 50 NS (0.73)
>55 42 12 30 29 23 19 55
Subtype DCIS 6 0 6 0 NS (0.13) 0 6 0 0.00014
Lum 
(ER+)
PR+ 28 9 19 32 16 12 57
PR- 10 4 6 40 10 0 100
HER2 5 2 3 40 4 1 80
TN 15 1 14 7 3 12 20
ER + 40 15 25 38 0.014 29 11 73 0.00087
- 16 1 15 6 4 12 25
PR + 30 10 20 33 NS (0.32) 19 11 63 NS (0.27)
- 26 6 20 23 14 12 54
HER2-
enrichied
+ 5 2 3 40 NS (0.44) 4 1 80 NS (0.19)
- 51 14 37 27 29 22 57
Menopause Pre 17 4 13 24 NS (0.80) 9 8 53 NS (0.98)
Post 45 12 33 27 24 21 53
T stage Tis 7 1 6 14 0.037 1 6 14 0.018
T1/2 47 10 37 21 25 22 53
T3/4 8 5 3 63 7 1 88
Nodal 
status
+ 28 5 23 18 NS (0.10) 15 13 54 NS (0.48)
- 27 10 17 37 17 10 63
Distant 
Metastasis
+ 3 1 2 33 NS (0.61) 3 0 100 NS (0.14)
- 53 15 38 28 30 23 57
Grade DCIS 6 0 6 0 NS (0.15) 0 6 0 0.0055
1 13 2 11 15 5 8 38
2/3 43 14 29 33 28 15 65
P was assessed by Pearson’s chi-squared test. NS, not significant; Tis, tumor in situ
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the idea that RECK-inducibility, as predicted by RPM, 
may be useful in predicting effectiveness of certain 
drugs, especially those activating RECK expression, in 
suppressing malignant growth and behaviors of breast 
cancer cells.
DISCUSSION
Previous study by Hill et al. [5] revealed a strong 
correlation between RIM found in tumor tissue and 
relapse of the disease, which underscored the critical 
role for RECK in tumor suppression. Practical value of 
RIM as a prognostic marker, however, depends on the 
availability of therapeutic options for subgroups of the 
disease to be identified, especially the one with higher 
risk. RPM developed in this study may be of value 
in this respect, since it provides information on drug 
sensitivity. For instance, RIM was positive in all cases 
(n=10) of ER+PR- tumors examined in this study, while 
RPM was positive only in 4 cases (Table 2). Similarly, 
a half of all RIM-positive luminal tumors (n=26) were 
also RPM-positive. According to our findings in vitro 
(Figure 2), treatment with both 5-azadC and MS275 may 
be required to upregulate RECK in RPM-positive tumors 
whereas MS275 alone may be sufficient to induce RECK 
in RPM-negative tumors. Although the exact biological 
responses of these particular tumors are unknown, our 
data in vitro (Figure 5) as well as several previous studies 
indicate its beneficial effects (tumor suppression). Hence, 
the tumors that require extensive therapies (about a half 
of RIM-positive cases) may be identified using RPM, 
in conjunction with RIM and conventional molecular 
markers (ER, PR, and HER2).
Two lines of new evidence indicate the involvement 
of CpG methylaiton, especially RIM, in RECK silencing. 
First, RIM was inversely correlated with the level of RECK 
mRNA/protein among the cell lines (Figure 1; Table 1) and 
tissue samples (Figure 4A–4C). Second, 5-azadC could 
convert RIM+ cell lines susceptible to the activity of MS275 
to induced RECK expression (Figure 2). This mechanism 
of silencing, however, probably operate only in later stages 
of mammary carcinogenesis, since RIM was negative in 
Figure 5: Effects of RECK-activation on the growth/survival of breast cancer cell lines. A, B. Effects of MS275, 5-azadC, 
or both on the growth/survival of T-47D cells. The cells (1×105/35-mm dish) plated on day 0 were incubated from day 1 to day 6 in growth 
medium or the medium containing 5-azadC (0.6 μM) with daily medium changes (red arrows), and then exposed to the same medium 
without or with MS275 (10 μM; blue arrow) from day 6 to day 8. Cell number was estimated by SF assay on day 1, 3, 6, and 8. Bar graph 
(A) represents mean ± s.e.m. (n=3). Representative micrographs at day 8 are also shown (B). C. Effects of MTX on four breast cancer cell 
lines. The cells were exposed to indicated concentrations of MTX for 48 h, and their number estimated by SF assay. The data represent 
mean ± s.e.m. (n=3). D. Effects of acute RECK expression on MTX-sensitivity of T-47D cells. T-47D cells were kept uninfected (Mock) or 
infected (MOI=600) with either control adenovirus (Ad-LacZ) or RECK-expressing virus (Ad-RECK). After 24 h, the cells were replated 
onto 96-well plates (1 × 104 cell/well), incubated for 16 h, exposed to MTX at various concentrations (0-10−4 M; triplicate) for 48 h, and 
then subjected to SF assay. Data (mean±SD) are presented as their ratios to the vehicle-treated controls. E, F. Effects of MS275 on Matrigel 
invasion of T-47D (E; 20-h incubation) or MDA-MB-231 cells (F; 16-h incubation). The graph represents mean±s.e.m. (n=3).
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MCF-10A (Figure 1B), most normal tissues (Figure 4B), 
and DCIS (Table 2) while it was more frequent in high-
grade carcinomas (28 of 43; 65%; Table 2).
ER+PR- breast cancers are known to be refractory to 
anti-estrogen treatment and prone to relapse [36]. A recent 
study indicate that progesterone inhibits estrogen-induced 
growth of ER+ breast tumors and that copy number loss 
of the PR gene is not rare among ER+ breast cancers [37]. 
The use of DNMT inhibitors in conjunctions with other 
therapeutic agents, such as anti-estrogens, Cdk inhibitors 
[38], HDAC inhibitors, or other RECK-activating agents 
[35], may have potential value in treating such tumors.
Our data (Supplementary Figure S7) suggest the 
involvement of HDAC1 in RECK gene repression. Our 
data also suggest the dominant nature of CpG methylation 
over this repression (Figure 2). We interpret that although 
both RPM and RIM are involved in RECK gene silencing, 
RPM probably represent a higher degree of silencing 
than RIM alone (Figure 4G). The RPM area spans the 
exon-1 and proximal promoter which harbors numerous 
potential cis-regulatory elements and has a feature of 
“CpG island shore” in which the degree of methylation 
can be influenced by external stimuli, tissue of origin, 
etc. [4, 39]. This may explain why RPM status varies 
among RIM-positive tumors and better predicts the cells’ 
ability to express RECK in response to MS275. It remains 
unknown, however, why two groups (RPM+ and RPM-) 
of RIM-positive luminal cancers arise.
MCF7 and T-47D are commonly used cell lines 
derived from luminal breast cancer. We found, however, 
that they differed in the pattern of RECK CpG methylation 
and RECK inducibility by chemicals. Molecular 
mechanisms by which these differences arise are important 
issues to be addressed in future studies. Some RIM-
negative cell lines show different basal levels of RECK 
expression (Figure 1D). For instance, in MDA-MB-231, 
basal RECK expression was moderate (Figure 1D, lane/
bar 10) and further upregulated by MS275 (Figure 2H), 
resulting in reduced Matrigel invasion (Figure 5F). 
Effects of MS275 and other HDAC inhibitors on RECK-
expression in, and the behaviors of, other RIM-negative 
cells may also yield important insights. Studies on the 
mechanism of action of MS275 in RECK-upregulation 
may also provide some clues to better understanding how 
RECK can be repressed in cancer cells.
MATERIALS AND METHODS
Cell culture
The mammary epithelial cell line (MCF-10A) and 
13 breast cancer cell lines (MCF7, MDA-MB-453, T-47D, 
ZR-75-1, SK-BR-3, MDA-MB-468, HCC1937, HCC1954, 
MDA-MB-231, BT549, Hs-578-T, HCC38, SUM-159PT) 
were obtained from ATCC. Two breast cancer cell lines, 
KPL-1 and KPL-3C, were described previously [40, 41]. 
Growth media used for maintainance of these cell lines are 
shown in Table 1 and were supplemented with fetal bovine 
serum (FBS; 5% for SUM-159PT and 10% for others).
Tissue samples
Breast cancer tissues from primary tumor sites were 
collected through needle biopsy or surgical resection 
performed in Department of Breast Surgery, Kyoto 
University Hospital. Prior written informed consents 
were obtained from all patients. The study protocols were 
approved by the Ethics Committee for Clinical Research, 
Kyoto University Hospital (authorization numbers G424). 
Obtained sample was quickly frozen in liquid nitrogen 
and stored under −80°C or liquid nitrogen until analyses. 
Samples collected between May 2011 and June 2014 
were used in this study. Pathological characterization was 
performed as described previously [42]. For molecular 
analyses, frozen tissues were homogenized using Bead 
Smash 12 (Waken-yaku, Kyoto, Japan), and the total DNA 
and RNA was extracted using QIAamp DNA Mini Kit 
(QIAGEN) and RNeasy Mini Kit (QIAGEN), respectively.
Methylation analysis of RECK gene
COBRA [23] was used to assess the methylation 
status of RECK gene. Bisulfite conversion of genomic 
DNA was performed using EpiTect Bisulfite kit (Qiagen). 
Primers for semi-nested PCRs are listed in Supplemental 
Table S1. Primary PCRs (reaction volume, 25 μl) were 
performed under the following conditions: 40 cycles of 
PCR [94°C, 30 s; 50°C, 30 s; 72°C, 60 s] followed by 
a final extension at 72°C for 5 min. Secondary PCRs 
were performed using 3 μl of the first PCR product as 
a template as follows: 45 cycles of PCR [94°C, 30 s; 
53°C, 30 s; 72°C, 60 s] followed by a final extension at 
72°C, 5 min. PCR products were digested with BstUI 
(Fermentas, UK) at 37°C for 4 h and resolved by agarose 
gel electrophoresis (1.5% agarose). For clone-sequencing, 
PCR products were cloned into pTA2 vector (TOYOBO), 
and 12 independent clones isolated were sequenced using 
T3 and T7 primers. Methylation index is defined as the 
ratio (%) of the number of methylated CpGs to the number 
all CpGs present in the fragment.
Quantitative reverse transcription-PCR
Total RNA was extracted using RNeasy Mini Kit 
(QIAGEN). The levels of specific mRNA were determined 
using SuperScript III Platinum SYBR Green One-Step 
qRT-PCR Kit (Invitrogen) with the Mx 3005P RealTime 
OCR System and Mx Pro software (Stratagene). Primers 
for RECK mRNA and HPRT mRNA (internal standard) are 
listed in Supplemental Table S1. The reaction conditions: 
an initial reverse transcription [50°C, 5 min; 95°C, 5 min] 
followed by 45 cycles of PCR [94 °C, 15 s; 54 °C (HPRT) 
or 64°C (hRECK), 40 s; 72°C, 20 s].
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Immunoblot assay
Immunoblot assay was performed as described by Oh 
et al. using the following antibodies [14]. Primary antibodies: 
RECK (5B11D12) [13], acetyl-Histone H4 (06-866, 
Millipore), HDAC1 (5356, CST), and GAPDH (AM4300, 
Ambion). The secondary antibodies: HRP-conjugated anti-
mouse IgG-F(ab’)2 monoclonal antibody (A4416, Sigma) 
and HRP-conjugated anti-Rabbit antibody (7074, CST).
siRNA transfection
Validated siRNAs for HDAC1 [HSS104725 (#1), 
HSS104726 (#2)] and a control siRNA (GC Duplex, 462001) 
were obtained from Invitrogen. The cells (2.5×105/well) were 
seeded onto six-well plates with DMEM supplemented with 
10% FBS without antibiotics. Sixteen hours after plating, 
siRNA was transfected using Lipofectamine RNAiMAX 
(Invitrogen) at a final RNA concentration of 100 nM.
Matrigel invasion assay
FluoroBlok Transwell insert of 8-μm pore size 
(Corning) were coated by adding 30 ul diluted Matrigel 
(BD Biosciences; 9.7 mg/ml) and air-dried overnight. The 
coated inserts were placed on a 24-well plate containing 
DMEM supplemented with 10% FBS as a chemo-
attractant. The cells (2.5×104) were suspended in DMEM 
containing 0.1% FBS and plated onto the insert. After 
16-h incubation, the cells invaded to the lower side of 
the membrane were stained with Calcein-AM (Dojindo, 
Japan) for 10 min, and then recorded using Microplate 
Fluorescence Reader (Molecular Devices, USA).
Adenovirus-mediated gene transfer
Construction of the control adenoviral vector 
(Ad-LacZ) and the vector expressing human RECK 
(Ad-RECK) have been described [43, 44]. Replication-
defective viruses were produced from these recombinant 
cosmids following the protocols of Miyake et al. [45].
Statistical analyses
Student’s t test was used to assess the significance 
of difference in RECK mRNA levels among different 
groups of tumor samples and in matrix invasion. 
Relationships between the RECK methylation status 
and clinicopathological parameters were evaluated by 
Pearson Chi-square tests using JMP software (ver.10, SAS 
Institute). The difference was considered significant when 
the P-value was smaller than 0.05.
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